中西医结合治疗囊肿型痤疮的临床疗效观察

目的评价中药消痤合剂联合异维A酸胶丸治疗囊肿型痤疮疗效。方法对囊肿型痤疮患者86例,随机分为两组,治疗组患者给予中药消痤合剂及异维A酸胶丸口服,对照组单纯异维A酸胶丸口服,分别于4、8、12周观察疗效。结果疗程结束后治疗组与对照组总有效率分别为93.2%、78.5%。结论中药消痤合剂联合异维A酸胶丸治疗囊肿型痤疮效果显著,不良反应低。     

中药消痤汤联合维A酸治疗寻常性痤疮疗效观察

目的:观察中药消痤汤内服联合0.025%维A酸外用治疗寻常性痤疮的临床疗效及安全性。方法:86例寻常性痤疮患者随机分为观察组和对照组各43例,观察组采用中药消痤汤煎服,1剂/d,对照组口服琥乙红霉素0.25 g,tid;两组均每晚1次用0.025%维A酸乳膏外涂,疗程6周。比较两组疗效与药品不良反应。结果:观察组和对照组愈显率分别为69.77%和41.86%,差异有统计学意义(P<0.01);总有效率分别为88.37%和69.77%,差异有统计学意义(P<0.05)。两组复发率分别为10.00%和22.22%,差异无统计学意义(P>0.05),两组均未发生严重不良反应。结论:中药消痤汤内服联合0.025%维A酸外用治疗寻常性痤疮有较好的临床疗效,安全性好。     

伊索霜治疗痤疮的实验研究与临床观察

目的:观察伊索霜对痤疮动物模型的影响及对寻常痤疮的治疗作用.方法:用维A酸霜作对照,以青春期♂家兔为实验对象,研究药物对痤疮动物模型的影响,以寻常痤疮患者为受试对象,观察该制剂的疗效.结果:伊索霜能明显缩小皮脂腺直径和毛囊面积,与基质对照组比较有统计学差异(P＜0.05,P＜0.01);伊索霜和维A酸霜的总有效率分别为86.7%和71.7%,差异有显著性(P＜0.05);两组的不良反应发生率分别为11.7%和10.0%,差异无显著性(P＞0.05).结论:伊索霜可缩小模型兔耳毛囊的面积和皮脂腺的直径,其临床疗效高于维A酸霜.     

异维A酸红霉素凝胶治疗痤疮的疗效观察

目的:观察异维A酸红霉素凝胶治疗轻、中度寻常痤疮的疗效。方法:将50例轻、中度面部寻常痤疮患者按面部左右侧分为2组,治疗组:左侧面部外用异维A酸红霉素凝胶,每晚1次;对照组:右侧面部外用维胺脂维E乳膏,每晚1次。比较第6周和第8周2组疗效。结果:治疗第6周时,治疗组与对照组的有效率分别为70%、42%(P<0.05);治疗第8周时,治疗组与对照组的有效率分别为82%、76%(P>0.05);对于炎性皮损,在治疗第6、8周时,2组疗效差异有统计学意义(P<0.05)。结论:异维A酸红霉素凝胶治疗轻、中度痤疮疗效确切,起效较维胺脂维E乳膏快。当皮损以炎性丘疹为主时,异维A酸红霉素凝胶疗效优于维胺脂维E乳膏。     

中西药联合治疗慢性湿疹

目的观察中药口服联合维A酸霜及醋酸曲安奈德乳膏外用治疗慢性湿疹的临床疗效。方法治疗组50例,口服中药痒疹冲剂,3g/次,2次/d,白天外用0.1%曲安奈德乳膏1次,晚上与0.025%维A酸霜混用1次,并进行封包。治疗组和对照组各50例,单纯用外用药。8周后判定疗效。结果治疗组总有效率90%,对照组总有效率74%,两组差异有统计学意义(P<0.05)。结论中西药联合治疗慢性湿疹临床疗效显著。     

维A酸乳膏联合除湿止痒软膏治疗寻常型痤疮临床观察

目的观察联合使用维A酸乳膏、除湿止痒软膏治疗寻常型痤疮的临床疗效及安全性。方法将93例患者随机分为2组:观察组48例患者采用0.1%维A酸乳膏联合除湿止痒软膏外用;对照组45例采用0.025%维A酸乳膏外用。治疗6周,每隔2周监测1次,进行疗效与安全性评价。结果观察组治愈率61.5%,总有效率89.6%;对照组治愈率24.4%,总有效率53.3%。2组有效率比较,差异有统计学意义(χ2=28.53,P<0.01)。结论维A酸乳膏联合除湿止痒软膏治疗寻常型痤疮,临床疗效明显优于维A酸乳膏单独使用,值得临床推荐。     

两种用药方案治疗寻常痤疮的成本-效果分析

目的：比较复方奥硝唑搽剂和维胺酯胶囊联合维A酸霜两种用药方案治疗寻常痤疮的疗效和经济学效果。方法：以76例寻常痤疮患者为对象,随机分为两组。甲组患者应用复方奥硝唑搽剂、乙组患者给予口服维胺酯胶囊和外用0.025%维A酸霜,在治疗1个疗程后,观察两组疗效,并运用经济学原理进行分析。结果：甲、乙两组有效率分别为86.84%,89.47%,效果无显著性差异（P〉0.05）;治疗成本分别为126.40元和257.52元,有显著性差异,两组的C/E分别为1.46和2.88。结论：两种用药方案治疗寻常痤疮的有效率无显著差异,但复方奥硝唑搽剂的经济效果优于维胺酯胶囊联合维A酸霜。     

异维A酸胶囊联合中药治疗痤疮154例

目的探讨异维A酸胶囊联合中药治疗痤疮的临床效果。方法对门诊154例痤疮患者,随机分为治疗组126例,对照组28例。治疗组给予维胺酯维E乳膏外用,口服异维A酸胶囊,并根据中医分型给于相应的中药汤剂口服。对照组给予维胺酯维E乳膏外用,口服异维A酸胶囊。对比分析两组治疗的临床效果。结果经过8周治疗,痊愈89例,显效22例,好转15例,痊愈和显效占88.09%,有效率100%。对照组28例,痊愈11例,显效9例,好转7例,痊愈和显效占71.42%,有效率96.42%。治疗组治愈和显效率明显高于对照组,具有显著差异性,χ2=6.56,P〈0.05。结论：异维A酸胶囊联合中药治疗痤疮,能够取得满意效果,具有提高疗效、缩短疗程、减少毒副作用。     

丹参酮联合维A酸乳膏及姜黄消痤擦剂治疗寻常性痤疮的临床观察

目的研究使用丹参酮口服联合维A酸乳膏及姜黄消痤擦剂外用治疗寻常性痤疮的临床疗效及安全性。方法将186例患者随机分为两组,试验组96例患者采用丹参酮胶囊口服,同时给予0.025%维A酸乳膏及姜黄消瘦擦剂外用。对照组90例患者给予阿齐霉素片口服,同时给予0.025%维A酸乳膏外用。治疗6周,每隔2周监测一次.进行疗效与安全性评价。结果试验组治愈率61.5%,有效率89.6%;对照组治愈率24.4%.有效率53.3%。两组有效率比较差异有统计学意义。结论治疗组使用中西医结合治疗方法治疗寻常性痤疮,临床疗效明显优于对照组,且不良反应轻微。     

阿维A联合咪喹莫特和维A霜治疗顽固性扁平疣疗效观察

目的：观察阿维A联合咪喹莫特和维A霜治疗顽固性扁平疣疗效。方法90例患者随机分为治疗组（48例）和对照组（42例）,治疗组口服阿维A 20mg,1日1次,每晚睡前交替隔日外涂咪喹莫特和0．1％维A酸乳膏,对照组每晚睡前交替隔日外涂咪喹莫特和0．1％维 A酸乳膏。结果经治疗8周后,治疗组痊愈36例,显效8例,有效3例,无效1例,有效率91．7％。对照组痊愈28例,显效8例,无效2例,有效率85．7％。结论阿维A联合咪喹莫特和维A霜治疗顽固性扁平疣疗效显著。     

红蓝光联合复方维A酸红霉素凝胶治疗痤疮疗效观察

目的：探讨红蓝光联合复方维A酸红霉素凝胶治疗痤疮的疗效。方法将228例患者随机分为治疗组（114例）和对照组（114例）。对照组：每晚外用复方维A酸红霉素凝胶。治疗组：红蓝光交替照射联合复方维A酸红霉素凝胶治疗。两组均治疗8周,在治疗后8、12周对两组患者进行疗效判定及比较。结果治疗组有效率为80.70%,对照组为56.14%,两组比较差异有统计学意义（P〈0.05）。结论红蓝光交替照射联合复方维A酸凝胶治疗痤疮疗效安全肯定。     

阿达帕林凝胶治疗寻常痤疮临床观察

目的 :观察 0 1%阿达帕林凝胶治疗寻常痤疮的临床疗效和安全性。方法 :16 0例寻常痤疮患者 ,分别给予外涂 0 1%阿达帕林凝胶 (80例 )及 0 0 2 5 %全反维A酸凝胶 (80例 )。根据治疗前后炎性损害和非炎性损害总数减少的百分率评价疗效。结果 :两组痊愈率、显效率、有效率均无统计学差异 ,阿达帕林组不良反应率明显低于全反维A酸组。结论 :0 1%阿达帕林是一种局部治疗寻常痤疮的有效的安全的药物     

Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris

Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The main indication of CTG is the management of moderate comedonal and mild-to-moderate papulopustular acne, an acne form which is present in more than 50% of acne patients. CTG can also be combined with systemic antiacne therapy, such as systemic isotretinoin, in nodulocystic acne. The product combines the anti-inflammatory and antibacterial properties of clindamycin with the well proven and beneficial comedolytic and anticomedogenic effects of tretinoin (all-trans retinoic acid). The addition of clindamycin to tretinoin enhances the comedolytic efficacy of tretinoin in moderate-to-severe acne of the face. The comedolytic activity of tretinoin and the anti-inflammatory efficacy of clindamycin accelerate resolution of all types of acne lesions without affecting the safety of both compounds. Discontinuation rates due to adverse events related to this formulation were found to be low (相似文献   

Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris

Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The main indication of CTG is the management of moderate comedonal and mild-to-moderate papulopustular acne, an acne form which is present in more than 50% of acne patients. CTG can also be combined with systemic antiacne therapy, such as systemic isotretinoin, in nodulocystic acne. The product combines the anti-inflammatory and antibacterial properties of clindamycin with the well proven and beneficial comedolytic and anticomedogenic effects of tretinoin (all-trans retinoic acid). The addition of clindamycin to tretinoin enhances the comedolytic efficacy of tretinoin in moderate-to-severe acne of the face. The comedolytic activity of tretinoin and the anti-inflammatory efficacy of clindamycin accelerate resolution of all types of acne lesions without affecting the safety of both compounds. Discontinuation rates due to adverse events related to this formulation were found to be low (≤ 1%). Safety of CTG use in pregnancy has not been established. The combination formulation is mainly designed to enhance effectiveness and minimize irritation. The once daily use of CTG, its rapid and dual effect and good tolerability have a positive impact on the duration of disease, patients' compliance and overall costs of therapy.     

Novel drug delivery systems: potential in improving topical delivery of antiacne agents

Acne is the most common cutaneous disorder of multifactorial origin with a prevalence of 70-85% in adolescents. The majority of the acne sufferers exhibit mild to moderate acne initially, which progresses to the severe form in certain cases. Topical therapy is employed as first-line treatment in mild acne, whereas for moderate and severe acne, systemic therapy is required in addition to topical therapy. Currently, several topical agents are available that affect at least one of the main pathogenetic factors responsible for the development of acne. Although topical therapy has an important position in acne treatment, side effects associated with various topical antiacne agents and the undesirable physicochemical characteristics of certain important agents like tretinoin and benzoyl peroxide affect their utility and patient compliance. Novel drug delivery strategies can play a pivotal role in improving the topical delivery of antiacne agents by enhancing their dermal localization with a concomitant reduction in their side effects. The current review emphasizes the potential of various novel drug delivery strategies like liposomes, niosomes, aspasomes, microsponges, microemulsions, hydrogels and solid lipid nanoparticles in optimizing and enhancing the topical delivery of antiacne agents.     

克林霉素磷酸酯外用溶液剂联合重组人表皮生长因子凝胶外用治疗轻中度痤疮疗效观察

目的：探讨克林霉素磷酸酯外用溶液剂联合重组人表皮生长因子凝胶外用治疗轻中度痤疮疗效.方法：将80例患者随机分为两组,治疗组40例采用克林霉素磷酸酯外用溶液剂涂擦皮损处,早晚各1次,重组人表皮生长因子凝胶外用皮损处,每日中午1次;对照组40例采用克林霉素磷酸酯外用溶液剂外涂皮损处,早晚各1次.8周后进行疗效判断.结果：治疗组和对照组总有效率分别为92.5％和82.5％,痊愈率分别为45％和30％,差异均有统计学意义（P＜0.05）.结论：克林霉素磷酸酯外用溶液剂联合重组人表皮生长因子凝胶治疗轻中度痤疮疗效优于单用克林霉素磷酸酯外用溶液剂.     

甲氨蝶呤治疗银屑病性关节炎临床观察

目的:观察甲氨蝶呤治疗银屑病性关节炎的疗效及不良反应。方法:选符合标准的该病患者59例,随机分为两组。治疗组予甲氨蝶呤治疗。对照组仅用维A酸类药物外用。结果:治疗组治愈11例,显效9例,好转8例,无效4例,总有效率为87.5%(95%CI=65.6～97.8%);对照组治愈2例,显效6例,好转5例,无效14例,总有效率为48.1%(95%CI=29.3～66.9%);两组综合疗效比较(Ⅱ=3.2531,P=0.0015),差异显著。结论:甲氨蝶呤治疗银屑病关节炎的临床疗效明显优于外用维A酸类药物,其收益OR=0.13(95%CI=0.04～0.47),NNT=3(95%CI=1.35～3.54)。     

甲氨蝶呤治疗银屑病性关节炎临床观察

目的:观察甲氨蝶呤治疗银屑病性关节炎的疗效及不良反应。方法:选符合标准的该病患者59例,随机分为两组。治疗组予甲氨蝶呤治疗,对照组仅用维A酸类药物外用。结果:治疗组治愈ll例,显效9例,好转8例,无效4例,总有效率为87.5%(95%CI=65.6～97.8%);对照组治愈2例,显效6例,好转5例,无效14例,总有效率为48.1%(95%CI=29.3～66.9%);两组综合疗效比较(Ⅱ=3.2531,P=0.0015),差异显著。结论:甲氨蝶呤治疗银屑病关节炎的临床疗效明显优于外用维A酸类药物,其收益OR=0.13(95%CI=0.04～0.47),NNT=3(95%CI=1.35～3.54)。     

止痒洗剂5种药材对4种致病菌体外抗菌效果初步研究

目的测定体外抗菌效果观察止痒洗剂的治疗作用。方法用微量肉汤稀释法和棋盘设计法对止痒洗剂中的苦参等5种药材对4种质控致病菌（细菌、霉菌）分别进行MIC检测,并计算其联合药敏指数FIC值。结果苦参、大黄、蛇床子、地肤子、防风等5种药材对4种质控菌金黄色葡萄球菌、大肠埃希菌、铜绿假单胞菌及白色念珠菌均有不同程度的抑菌作用,且联用（即处方药）的抑菌作用要更明显,FIC值计算结果5种药材在方中起着协同作用和相加作用,而无拮抗作用。结论止痒洗剂组方合理。